Last reviewed · How we verify
Regular Insulin via Insulin-Glucose Algorithm
Regular Insulin via Insulin-Glucose Algorithm is a Small molecule drug developed by Stanford University. It is currently in Phase 1 development.
Regular Insulin is a protein-based insulin receptor agonist that acts as an agonist to the insulin receptor. It is used to treat conditions such as diabetes, and its administration can be guided by computer algorithms to achieve optimal glucose control.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Regular Insulin via Insulin-Glucose Algorithm |
|---|---|
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis (NA)
- Automated Insulin for Management of Intrapartum Glycemia (NA)
- Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management (NA)
- Feasibility and Performance of Continuous Glucose Monitoring to Guide Computerized Insulin Infusion Therapy in Non-ICU Patients Receiving Corticosteroid Therapy and Specialized Nutrition (NA)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL (EARLY_PHASE1)
- Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total Pancreatectomy (PHASE3)
- Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regular Insulin via Insulin-Glucose Algorithm CI brief — competitive landscape report
- Regular Insulin via Insulin-Glucose Algorithm updates RSS · CI watch RSS
- Stanford University portfolio CI
Frequently asked questions about Regular Insulin via Insulin-Glucose Algorithm
What is Regular Insulin via Insulin-Glucose Algorithm?
Who makes Regular Insulin via Insulin-Glucose Algorithm?
What development phase is Regular Insulin via Insulin-Glucose Algorithm in?
Related
- Manufacturer: Stanford University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing